Different BET Protein Actions Shape Cancer Drug Effectiveness

A study from the Max Planck Institute of Immunobiology and Epigenetics explains why drugs known as BET inhibitors have often underperformed in cancer trials. The findings reveal that two closely related BET proteins, BRD2 and BRD4, perform distinct functions during gene activation —a difference that significantly influences how these drugs work.

For more than a decade, BET inhibitors have been tested as anticancer agents based on the idea that blocking BET proteins would suppress tumor growth by hindering oncogene activation. While experiments in cell systems showed encouraging results, clinical responses have been limited, with unpredictable effects and substantial toxicity. These outcomes reflected an early assumption: that all BET proteins behaved similarly and could be targeted as a single group.

The team led by Asifa Akhtar offers a more refined view. Their study shows that BRD4 regulates the stage where RNA Polymerase II releases genes into active transcription, whereas BRD2 functions earlier, organizing and assembling the machinery required for initiation. Blocking both proteins at once therefore interferes with two distinct phases of gene activation, creating complex and variable consequences for the cell. “Think of gene activation like stage production. BRD2 sets up the stage: assembling the props, costumes and actors to ensure preparations run smoothly. BRD2 then gives BRD4, the actor, the “start” signal to begin with the performance,” Akhtar explains.

BRD2 had long been overshadowed by BRD4, but the research highlights its unique responsiveness to chromatin modifications. The enzyme MOF places chemical marks called histone acetylations that act as genomic bookmarks. BRD2 relies on these acetylations to anchor itself to chromatin, and when MOF is removed, BRD2 can no longer bind effectively, while other BET proteins remain largely unaffected. “The findings support a model in which acetylated chromatin creates a platform that allows regulatory proteins like BRD2 to concentrate and prepare the transcription machinery for when it will be needed,” notes Umut Erdogdu, first author of the study published in Nature Genetics.

Beyond this specificity, BRD2 forms molecular clusters at gene sites, concentrating transcription components exactly where activity begins. Removing the clustering region halted gene transcription nearly as much as deleting BRD2 itself, confirming its functional necessity. The study suggests that future therapies could benefit from distinguishing between BRD2 and BRD4 actions, enabling drug designs that target their separate roles rather than blocking both indiscriminately.